Orthofuse has raised £2.2m in a seed round to develop 3D-printed implant systems designed to improve safety and efficiency in orthopaedic surgery.
The orthopaedic medtech company is developing implants for orthopaedic trauma and spinal degenerative conditions, procedures that can be technically demanding and time-sensitive, particularly when bone quality is poor.
Orthofuse said current implant systems can be difficult to use consistently across varied clinical scenarios and cannot be repositioned without causing significant tissue damage.
The company said these limitations can prolong surgery times and increase risks for both patients and clinicians.
The company said its approach uses additive manufacturing and novel implant architectures to improve the reversibility of procedures in challenging cases, reduce the number of surgical steps and ensure strong fixation.
The funding will support technical development, regulatory readiness and partnerships as Orthofuse prepares for early-stage clinical evaluations.
James Scott, co-founder and chief executive of Orthofuse, said: “Modern surgical practice demands implant systems that reflect the realities of the operating room.
“Orthofuse is developing a technology designed to simplify procedures, giving surgeons greater flexibility and confidence.
“This investment enables us to accelerate progress toward setting a new standard for safety and efficiency in orthopaedic care.”
The round was led by a group of angel investors, with participation from ACF Investors, Cambridge Angels and Empirical Ventures.
Didier Cowling, lead investor and board member, said: “Orthofuse has reimagined the fundamental architecture of implants to solve the inefficiencies of current solutions.
“We believe this approach has real value in improving orthopaedic care, and are pleased to support the team as they move forward.”
Tim Mills, managing partner at ACF Investors, said: “Orthofuse is tackling a critical challenge in surgery by coupling advanced engineering and clinical practicality.
“James and his team have developed a truly innovative approach to implant architecture that has the potential to significantly improve patient outcomes whilst enhancing surgical efficiency, and we are delighted to support them in this journey.”
